Medite Cancer Diagnostics, Inc.
MDIT
$0.00
$0.000.00%
| 09/30/2018 | 06/30/2018 | 03/31/2018 | 12/31/2017 | 09/30/2017 | |
|---|---|---|---|---|---|
| Revenue | 41.99% | 78.15% | -20.41% | 0.36% | -27.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.99% | 78.15% | -20.41% | 0.36% | -27.92% |
| Cost of Revenue | -29.76% | -1.06% | -3.39% | 91.34% | -1.42% |
| Gross Profit | 298.10% | 2,063.27% | -50.74% | -313.21% | -63.21% |
| SG&A Expenses | 8.97% | -37.95% | 17.52% | 109.53% | 45.12% |
| Depreciation & Amortization | -43.64% | 25.93% | 44.90% | 33.33% | 107.55% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.66% | -18.88% | -0.08% | 70.98% | 21.30% |
| Operating Income | 93.27% | 98.21% | -66.67% | -212.08% | -556.74% |
| Income Before Tax | 54.21% | 65.52% | -46.81% | -170.57% | -412.78% |
| Income Tax Expenses | -- | 0.00% | -- | -312.61% | -- |
| Earnings from Continuing Operations | 54.21% | 65.35% | -46.81% | -154.21% | -424.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.21% | 65.35% | -46.81% | -154.21% | -424.51% |
| EBIT | 93.27% | 98.21% | -66.67% | -212.08% | -556.74% |
| EBITDA | 97.47% | 102.65% | -68.69% | -223.77% | -703.70% |
| EPS Basic | 82.11% | 83.36% | 14.55% | -89.43% | -278.71% |
| Normalized Basic EPS | 82.60% | 83.93% | -3.23% | -111.76% | -293.48% |
| EPS Diluted | 82.11% | 83.36% | 14.55% | -89.43% | -278.71% |
| Normalized Diluted EPS | 82.60% | 83.93% | -3.23% | -111.76% | -293.48% |
| Average Basic Shares Outstanding | 161.29% | 114.43% | 70.77% | 32.57% | 30.22% |
| Average Diluted Shares Outstanding | 161.29% | 114.43% | 70.77% | 32.57% | 30.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
